Showing 1 - 7 results of 7 for search 'Peter Nash', query time: 0.02s Refine Results
  1. 1
    Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

    Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib by Peter Nash, Stephen Hall, Paul Bird, Carol A Connell, Kenneth Kwok, David Witcombe, Krishan Thirunavukkarasu

    Published 2019-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors

    Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and pr... by Peter Nash, Frank Behrens, Ana-Maria Orbai, Suchitrita S Rathmann, David H Adams, Olivier Benichou, Atul Deodhar

    Published 2018-09-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized controlled study: a post hoc analysis

    Efficacy and safety of tofacitinib in an open-label, long-term extension study in patients with psoriatic arthritis who received adalimumab or tofacitinib in a Phase 3 randomized c... by Dafna D. Gladman, Peter Nash, Philip J. Mease, Oliver FitzGerald, Stephanie Duench, Mary Jane Cadatal, Karim R. Masri

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study

    Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study by Peter C. Taylor, Walid Fakhouri, Samuel Ogwu, Ewa Haladyj, Inmaculada de la Torre, Bruno Fautrel, Rieke Alten, Peter Nash, Eugen Feist

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study

    Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Laure Gossec, Peter Nash, Philip J Mease, Emmanouil Rampakakis, Laura C Coates, Philip S Helliwell, Alexa P Kollmeier, Xie L Xu, May Shawi, Miriam Zimmermann, Natalie J Shiff

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Impact of filgotinib on pain control in the phase 3 FINCH studies

    Impact of filgotinib on pain control in the phase 3 FINCH studies by Bruno Fautrel, Peter Nash, Arthur Kavanaugh, Peter C Taylor, René Westhovens, Rieke Alten, Janet Pope, Dick de Vries, Chris Watson, Georg Pongratz, Pieter-Jan Stiers, Ken Hasegawa, Shangbang Rao

    Published 2024-02-01
    Get full text
    Article
    Save to List
    Saved in:
  7. 7
    Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study

    Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3,... by Philip J. Mease, Xenofon Baraliakos, Vinod Chandran, Enrique R. Soriano, Peter Nash, Atul Deodhar, Emmanouil Rampakakis, Natalie J. Shiff, Soumya D. Chakravarty, May Shawi, Joseph F. Merola, Iain B. McInnes

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: